- Home
- CLW vs TSHA Comparison
CLW vs TSHA Comparison
Compare CLW & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLW
- TSHA
- Stock Information
- Founded
- CLW 2005
- TSHA 2019
- Country
- CLW United States
- TSHA United States
- Employees
- CLW N/A
- TSHA N/A
- Industry
- CLW Paper
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- CLW Basic Materials
- TSHA Health Care
- Exchange
- CLW Nasdaq
- TSHA Nasdaq
- Market Cap
- CLW 430.4M
- TSHA 403.7M
- IPO Year
- CLW N/A
- TSHA 2020
- Fundamental
- Price
- CLW $26.68
- TSHA $2.18
- Analyst Decision
- CLW Buy
- TSHA Strong Buy
- Analyst Count
- CLW 1
- TSHA 8
- Target Price
- CLW $37.00
- TSHA $6.63
- AVG Volume (30 Days)
- CLW 655.9K
- TSHA 6.7M
- Earning Date
- CLW 11-04-2024
- TSHA 11-13-2024
- Dividend Yield
- CLW N/A
- TSHA N/A
- EPS Growth
- CLW N/A
- TSHA N/A
- EPS
- CLW 0.88
- TSHA N/A
- Revenue
- CLW $2,211,900,000.00
- TSHA $9,915,000.00
- Revenue This Year
- CLW N/A
- TSHA N/A
- Revenue Next Year
- CLW N/A
- TSHA N/A
- P/E Ratio
- CLW $30.30
- TSHA N/A
- Revenue Growth
- CLW 58.65
- TSHA N/A
- 52 Week Low
- CLW $24.17
- TSHA $1.19
- 52 Week High
- CLW $57.13
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- CLW 49.63
- TSHA 56.47
- Support Level
- CLW $24.17
- TSHA $1.96
- Resistance Level
- CLW $30.04
- TSHA $2.34
- Average True Range (ATR)
- CLW 1.31
- TSHA 0.26
- MACD
- CLW 0.04
- TSHA 0.06
- Stochastic Oscillator
- CLW 42.76
- TSHA 68.75
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and selling of private label tissue, paperboard, and pulp-based products. The company has two reportable segments namely the consumer products segment which manufactures and sells a complete line of at-home tissue products as well as AFH products. The pulp and paperboard segment manufactures and markets bleached paperboard for the high-end segment of the packaging industry as well as offers services that include custom sheeting, slitting and cutting of paperboard. It generates maximum revenue from Pulp and Paperboard segment. Geographically, it derives maximum revenue from the United States.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.